Cargando…
Cryotherapy for nodal metastasis in NSCLC with acquired resistance to immunotherapy
Novel approaches with checkpoint inhibitors in immunotherapy continue to be essential in the treatment of non-small cell lung cancer (NSCLC). However, the low rate of primary response and the development of acquired resistance during the immunotherapy limit their long-term effectiveness. The underly...
Autores principales: | Adam, Lucas C., Raja, Junaid, Ludwig, Johannes M., Adeniran, Adebowale, Gettinger, Scott N., Kim, Hyun S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6292083/ https://www.ncbi.nlm.nih.gov/pubmed/30541627 http://dx.doi.org/10.1186/s40425-018-0468-x |
Ejemplares similares
-
Oncolytic virus immunotherapy: future prospects for oncology
por: Raja, Junaid, et al.
Publicado: (2018) -
The Landscape of Immunotherapy Resistance in NSCLC
por: Frisone, Daniele, et al.
Publicado: (2022) -
Erratum: The landscape of immunotherapy resistance in NSCLC
Publicado: (2023) -
Effect and Tolerability of Immunotherapy in Patients with NSCLC with or without Brain Metastasis
por: Bjørnhart, Birgitte, et al.
Publicado: (2022) -
Microenvironment and the progress of immunotherapy in clinical practice of NSCLC brain metastasis
por: Xie, Mengqing, et al.
Publicado: (2023)